PCSK9 and cardiovascular disorder: Thus, PCSK9 inhibitors reduce cardiovascular disease risk alone and in combination with statins despite some cases in actual clinical situations where lowering the LDL-C below the goal is difficult due to the adverse effects of statins or other causes [66,67,68].